Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE AF versus TIMOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE AF versus TIMOLOL.
BETAPACE AF vs TIMOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sotalol is a class III antiarrhythmic agent that also has non-cardioselective beta-adrenergic receptor blocking activity. It prolongs the cardiac action potential duration by blocking potassium channels (IKr), thereby prolonging the QT interval and refractory periods.
Nonselective beta-adrenergic receptor antagonist (beta-blocker) that competively blocks beta-1 and beta-2 receptors, reducing heart rate, contractility, and cardiac output. In glaucoma, decreases intraocular pressure by reducing aqueous humor production.
80 mg orally twice daily. For atrial fibrillation/flutter, initiate at 80 mg twice daily; may increase after 2-3 days to 120 mg twice daily if needed. Maximum 120 mg twice daily.
0.25-0.5 mg ophthalmic solution instilled twice daily; for oral: 10-20 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTimolol + Digoxin
"Timolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTimolol + Digitoxin
"Timolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateTimolol + Deslanoside
"Timolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateTimolol + Acetyldigitoxin
"Timolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal elimination half-life: 12 hours (range 10–20 hours) in patients with normal renal function; prolonged in renal impairment (up to 42 hours in severe impairment).
Terminal half-life: 4-5 hours (healthy adults); prolonged to 7-10 hours in renal impairment, 11-16 hours in hepatic impairment; clinical context: once-daily dosing for hypertension/glaucoma.
Primarily renal (unchanged drug and metabolites); approximately 40% excreted as unchanged sotalol in urine, with additional metabolites via fecal route (~10%). Biliary excretion minimal (<5%).
Renal: ~20% unchanged; hepatic metabolism accounts for ~80%, with metabolites excreted renally; minor biliary/fecal elimination (<5%).
Category C
Category A/B
Beta-Blocker
Beta-Blocker